Advertisement

Prognostic Indicators and Treatment of IgA Nephropathy in China

  • Wei-Bo Le
  • Zhi-Hong LiuEmail author
Chapter

Abstract

IgA nephropathy (IgAN) accounts for 45 % of the primary glomerulonephritis in China. The 10- and 20-year cumulative renal survival rates were 83 % and 64 %, respectively, in a cohort of 1,155 Chinese patients with IgAN. The levels of estimated glomerular filtration rate (eGFR), proteinuria, hypoproteinemia, hypertension and hyperuricemia are the five most important clinical risk factors independently associated with renal outcome. Pathologically, the lesions of mesangial proliferation and tubular interstitial fibrosis correlated independently with prognosis of patients with IgAN. IgAN patients with minimal change disease and those with recurrent macro-hematuria are considered distinct subtypes of IgAN and have a relatively favorable renal prognosis. Using repeat renal biopsy data, we found that active proliferative lesions (glomerular endocapillary hypercellularity, crescent, or necrosis) are reversible after immunosuppressive treatment. The renal pathological lesion-based guidance for treatment options provides new tools for individual therapy in IgAN patients.

Keywords

IgA nephropathy Prognosis Treatment 

Notes

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24(3):179–96. doi:S0270929504000038 [pii].CrossRefPubMedGoogle Scholar
  2. 2.
    Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004;66(3):920–3. doi: 10.1111/j.1523-1755.2004.00837.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013;84(5):1017–24. doi: 10.1038/ki.2013.210.CrossRefPubMedGoogle Scholar
  4. 4.
    Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18(5):503–12.PubMedGoogle Scholar
  5. 5.
    Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479–85. doi: 10.1093/ndt/gfr527.CrossRefPubMedGoogle Scholar
  6. 6.
    Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014;9(3):e91756. doi: 10.1371/journal.pone.0091756.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, et al. Mortality of IgA nephropathy patients: a single center experience over 30 years. PLoS One. 2012;7(12):e51225. doi: 10.1371/journal.pone.0051225.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gutierrez E, Zamora I, Ballarin JA, Arce Y, Jimenez S, Quereda C, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012;23(10):1753–60. doi: 10.1681/ASN.2012010063.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Moreno JA, Martin-Cleary C, Gutierrez E, Rubio-Navarro A, Ortiz A, Praga M, et al. Haematuria: the forgotten CKD factor? Nephrol Dial Transplant. 2012;27(1):28–34. doi: 10.1093/ndt/gfr749.CrossRefPubMedGoogle Scholar
  10. 10.
    Le W, Liang S, Chen H, Wang S, Zhang W, Wang X, et al. Long-term outcome of IgA nephropathy patients with recurrent macroscopic hematuria. Am J Nephrol. 2014;40(1):43–50. doi: 10.1159/000364954.CrossRefPubMedGoogle Scholar
  11. 11.
    Eitner F, Floege J. In search of a better understanding of IgA nephropathy-associated hematuria. Kidney Int. 2012;82(5):513–5. doi: 10.1038/ki.2012.160.CrossRefPubMedGoogle Scholar
  12. 12.
    Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986;26(4):174–80.PubMedGoogle Scholar
  13. 13.
    Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56. doi: 10.1038/ki.2009.168.CrossRefPubMedGoogle Scholar
  14. 14.
    Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45. doi: 10.1038/ki.2009.243.CrossRefPubMedGoogle Scholar
  15. 15.
    Roberts IS. Oxford classification of immunoglobulin A nephropathy: an update. Curr Opin Nephrol Hypertens. 2013. doi: 10.1097/MNH.0b013e32835fe65c.PubMedGoogle Scholar
  16. 16.
    Zeng CH, Le W, Ni Z, Zhang M, Miao L, Luo P, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012;60(5):812–20. doi: 10.1053/j.ajkd.2012.06.011.CrossRefPubMedGoogle Scholar
  17. 17.
    Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol. 2011;6(9):2175–84. doi: 10.2215/CJN.11521210.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Le W, Zeng CH, Liu Z, Liu D, Yang Q, Lin RX, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol. 2012;13:158. doi: 10.1186/1471-2369-13-158.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015. doi: 10.1007/s40620-014-0165-x.PubMedGoogle Scholar
  20. 20.
    Wang J, Juan C, Huang Q, Zeng C, Liu Z. Corticosteroid therapy in IgA nephropathy with minimal change-like lesions: a single-centre cohort study. Nephrol Dial Transplant. 2013;28(9):2339–45. doi: 10.1093/ndt/gft211.CrossRefPubMedGoogle Scholar
  21. 21.
    Tang Z, Wu Y, Wang QW, Yu YS, Hu WX, Yao XD, et al. Idiopathic IgA nephropathy with diffuse crescent formation. Am J Nephrol. 2002;22(5–6):480–6. doi:ajn22480 [pii].CrossRefPubMedGoogle Scholar
  22. 22.
    Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118–25. doi: 10.1681/ASN.2012101017.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.National Clinical Research Center of Kidney Diseases, Jinling HospitalNanjing University School of MedicineNanjingChina

Personalised recommendations